| scholarly article | Q13442814 |
| P50 | author | Jens Juul Holst | Q28373106 |
| Sten Madsbad | Q39034312 | ||
| Kirstine N Bojsen-Møller | Q50788548 | ||
| Rune E. Kuhre | Q51525823 | ||
| Maria S Svane | Q56451929 | ||
| Jens F. Rehfeld | Q92099028 | ||
| Trine R Clausen | Q114444592 | ||
| P2093 | author name string | Viggo B Kristiansen | |
| Signe Nielsen | |||
| P2860 | cites work | A G protein-coupled receptor responsive to bile acids | Q24338558 |
| Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus | Q24535547 | ||
| The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control | Q24629879 | ||
| Bile acids, obesity, and the metabolic syndrome | Q27020976 | ||
| Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells | Q27324038 | ||
| Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans | Q27865308 | ||
| FXR is a molecular target for the effects of vertical sleeve gastrectomy | Q28236848 | ||
| Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man | Q28609252 | ||
| Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes | Q33746480 | ||
| Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity | Q34146701 | ||
| Release of GLP-1 and PYY in response to the activation of G protein-coupled bile acid receptor TGR5 is mediated by Epac/PLC-ε pathway and modulated by endogenous H2S. | Q34441486 | ||
| Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. | Q35577851 | ||
| Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism | Q35808233 | ||
| The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs | Q35910048 | ||
| Bile Acids Trigger GLP-1 Release Predominantly by Accessing Basolaterally Located G Protein-Coupled Bile Acid Receptors | Q36164320 | ||
| Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. | Q36736464 | ||
| A surgical model in male obese rats uncovers protective effects of bile acids post-bariatric surgery. | Q36946081 | ||
| Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. | Q37110621 | ||
| Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass | Q38005896 | ||
| Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery | Q38060843 | ||
| The bile acid sensor FXR regulates insulin transcription and secretion | Q39754250 | ||
| Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion | Q39989391 | ||
| Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial. | Q40611822 | ||
| In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans | Q40953070 | ||
| Diabetes: the search for mechanisms underlying bariatric surgery. | Q41859691 | ||
| Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial | Q42440562 | ||
| Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass | Q42449157 | ||
| Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon | Q43214811 | ||
| Effects of chenodeoxycholic acid on the secretion of gut peptides and fibroblast growth factors in healthy humans | Q43426768 | ||
| Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. | Q44581393 | ||
| Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects | Q44621765 | ||
| Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers | Q44964426 | ||
| Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. | Q45943724 | ||
| Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans. | Q46011128 | ||
| Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. | Q47253610 | ||
| Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. | Q51310555 | ||
| Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. | Q51357717 | ||
| Bile Diversion in Roux-en-Y Gastric Bypass Modulates Sodium-Dependent Glucose Intestinal Uptake | Q57137769 | ||
| Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery | Q57154153 | ||
| Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery | Q58167278 | ||
| Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux-en-Y gastric bypass | Q58167703 | ||
| Evidence of Extrapancreatic Glucagon Secretion in Man | Q58447369 | ||
| Glucose stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1 and GLUT2, leading to cell depolarization and calcium influx | Q58447507 | ||
| An Analysis of Cosecretion and Coexpression of Gut Hormones From Male Rat Proximal and Distal Small Intestine | Q58447548 | ||
| Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man | Q58449161 | ||
| Circulating glucagon after total pancreatectomy in man | Q58449447 | ||
| Effects of Taurocholic Acid on Glycemic, Glucagon-like Peptide-1, and Insulin Responses to Small Intestinal Glucose Infusion in Healthy Humans | Q62478874 | ||
| Accurate measurement of cholecystokinin in plasma | Q74557941 | ||
| Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery | Q84403383 | ||
| P433 | issue | 3 | |
| P577 | publication date | 2017-02-14 | |
| P1433 | published in | Physiological Reports | Q15716763 |
| P1476 | title | Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass | |
| P478 | volume | 5 |
| Q52588032 | Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. |
| Q90731281 | Bile acids in glucose metabolism and insulin signalling - mechanisms and research needs |
| Q92958123 | CCK-1 and CCK-2 receptor agonism do not stimulate GLP-1 and neurotensin secretion in the isolated perfused rat small intestine or GLP-1 and PYY secretion in the rat colon |
| Q64910353 | Chenodeoxycholic Acid Ameliorates AlCl3-Induced Alzheimer's Disease Neurotoxicity and Cognitive Deterioration via Enhanced Insulin Signaling in Rats. |
| Q57107215 | GLP-2 receptor signaling controls circulating bile acid levels but not glucose homeostasis in Gcgr mice and is dispensable for the metabolic benefits ensuing after vertical sleeve gastrectomy |
| Q88187893 | Gut microbiota: Inulin regulates endothelial function: a prebiotic smoking gun? |
| Q55081525 | Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. |
| Q47842186 | Obesity, body weight regulation and the brain: Insights from fMRI. |
| Q91121478 | Physiology of the Incretin Hormones, GIP and GLP-1-Regulation of Release and Posttranslational Modifications |
| Q47109985 | Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice |
Search more.